Physician profile
Johnathon Wilde
NPI 1073231999
$1,152.60
in general payments reported to CMS, 2019-2025
22 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $84.14 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $288.06 | 2024-2025 | Fanapt |
| Abbvie INC. | $226.39 | 2025 | |
| Corcept Therapeutics | $105.73 | 2024-2025 | Korlym |
| Antares Pharma, INC. | $86.28 | 2025 | Xyosted |
| Lilly USA, LLC | $71.72 | 2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $63.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.11 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $29.64 | 2025 | Farxiga |
| Boston Scientific Corporation | $22.06 | 2025 | Watchman Access System |
| Shield Therapeutics INC | $20.75 | 2025 | |
| Sumitomo Pharma America, INC. | $18.89 | 2025 | Gemtesa |
| Dexcom, INC. | $18.76 | 2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $18.15 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $17.92 | 2025 | Iqirvo |
| Seqirus USA INC | $17.80 | 2025 | Flucelvax |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $16.80 | 2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $16.58 | 2025 | Rexulti |
| Csl Behring | $15.62 | 2025 | Haegarda |
| Merck Sharp & Dohme LLC | $14.83 | 2025 | Enflonsia, Capvaxive |
| Collegium Pharmaceutical, INC. | $13.60 | 2025 | Jornay Pm |
| Phathom Pharmaceuticals, INC. | $12.51 | 2025 | Voquezna |
| Corium, LLC | $7.40 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathon Wilde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.